Ernst-Günter Afting, Ph.D., M.D.
Dr. Afting has served as a director since 1996. From 1995 until his retirement in 2006, Dr. Afting served as president and chief executive officer of the National Research Center for Environment and Health, GSF-National Research Center for Environment and Health GmbH, a governmental research center in Munich, Germany. From 1993 to 1995, he served as president and chief executive officer of Roussel UCLAF, Paris. He was also a member of the board of the Pharmaceutical Division of Hoechst Group from 1984 to 1993 and was chairman and chief executive officer of the Divisional Pharmaceutical Board of Hoechst from 1992-1993. Dr. Afting was a member of the advisory committee on science and technology to German Chancellor Helmut Kohl from 1996 to 1997 and from 1996 to 2005 was a member of the German National Advisory Committee on Health Research to the State Secretaries of Science, Technology and Health. Dr. Afting has been a member of the medical faculty at the University of Goettingen since 1985. Dr. Afting currently serves on the boards of Intercell AG, Enanta Pharmaceuticals, Inc., and Olympus Europa GmbH. He received his Ph.D. in Chemistry and M.D. from the University of Freiburg/Breisgau, Germany.
Kenneth F. Buechler, Ph.D.
Kenneth F. Buechler, Ph.D., was president, chief scientific officer and co-founder of Biosite Incorporated. From 1988 to 1994, Dr. Buechler was Biosite's director of chemistry. Prior to forming Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated in San Diego. Dr. Buechler received his doctorate in biochemistry and his bachelor’s degree in chemistry from Indiana University. Dr. Buechler sits on the boards of Quidel Corp., Sotera Wireless Inc., Adnavance Inc., and Astute Medical Inc.
John A. Fazio
Mr. Fazio has served as a director since 2007. Mr. Fazio is a former senior general practice partner of PricewaterhouseCoopers, a global accounting and professional services company. Mr. Fazio retired from PricewaterhouseCoopers in 2000 following 35 years of service during which he held a variety of senior positions in accounting, auditing, consulting, and administration at PricewaterhouseCoopers. Currently, Mr. Fazio serves on the board of directors of Heidrick & Struggles International, Inc. Mr. Fazio is a member of the American Institute of Certified Public Accountants and the Institute of Management Accountants and holds an M.A. from Ohio State University.
David Pendarvis, Esq.
David Pendarvis is senior vice president – organizational development, global general counsel and secretary of ResMed Inc., a medical device company focused on sleep-disordered breathing. He has been with ResMed since 2002. From 2000 until 2002, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP. Until 2000 he was a partner with Gibson, Dunn & Crutcher LLP, where he began working in 1986. From 1984 until 1986 he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis received his J.D. from the University of Texas School of Law; a MS in executive leadership from the University of San Diego, and a BA from Rice University.
Harry F. Hixson, Jr., Ph.D.
Dr. Hixson serves as the company's chief executive officer. Dr. Hixson has served as chairman of the board of directors since 2003. He recently served on the board of directors of BrainCells, Inc., a biopharmaceutical company focused on central nervous system drug development, where he was chief executive officer from July 2004 until September 2005. Dr. Hixson served as chief executive officer of Elitra Pharmaceuticals, Inc., a biopharmaceutical company focused on anti-infective drug development, from February 1998 until May 2003. He served as president and chief operating officer of Amgen Inc., and as a member of its board of directors from 1988 to 1991. Prior to Amgen, Dr. Hixson held various management positions with Abbott Laboratories, including vice president, diagnostic products business group, and vice president, research and development, in the Diagnostics Division. Dr. Hixson also is a director of Arena Pharmaceuticals, Inc. Dr. Hixson received his Ph.D. in Physical Biochemistry from Purdue University and an M.B.A. from the University of Chicago.
Myla Lai-Goldman, M.D.
Dr. Lai-Goldman has been a Director since 2012. She is a managing partner at Personalized Science, LLC, and Chief Executive Officer of GeneCentric Diagnostics, Inc. and a Venture Partner with Hatteras Venture Partners. She previously served as Executive Vice President, Chief Medical Officer and Chief Scientific Officer of Laboratory Corporation of America. Dr. Lai-Goldman received her undergraduate degree in biology from the University of Pennsylvania and her medical degree from Columbia University. She completed a pathology residency and surgical pathology fellowship at UCLA in Los Angeles, and followed with a hematopathology fellowship at the University of North Carolina at Chapel Hill.
Richard A. Lerner, M.D.
Dr. Lerner has served as a director since 2007. Dr. Lerner has been president of the Scripps Research Institute, a private, non-profit biomedical research organization, since 1986. Dr. Lerner received the Wolf Prize in Chemistry in 1994, the California Scientist of the Year Award in 1996, and the Paul Ehrlich and Ludwig Darmstaedter Prize in 2003 for his achievements in the development of catalytic antibodies and combinatorial antibody libraries. Dr. Lerner is a member of the Royal Swedish Academy of Sciences and the National Academy of Sciences. Dr. Lerner currently serves as a director of Kraft Foods, Inc., Opko Health, Inc., Xencor, Inc., and Intra-Collular Therapies. Dr. Lerner received his M.D. degree from Stanford Medical School.
Charles P. Slacik
Mr. Slacik has served as chief financial officer and senior vice president of Finance for Beckman Coulter since October 2006. He is currently responsible for all aspects of financial management and information technology for Beckman Coulter. Prior to joining Beckman Coulter, Mr. Slacik was executive vice president and chief financial officer at Watson Pharmaceuticals, a specialty pharmaceutical company in Corona, California. Before that, he served as senior vice president and chief financial officer at C.R. Bard, Inc., which develops and manufactures medical technologies in the fields of vascular, urology, oncology and surgical specialty products. Mr. Slacik earned a Bachelor of Science degree in accounting and finance from the University of Connecticut and is a Certified Public Accountant. He is currently a member of the Orange County Chapter of Financial Executives International and the Connecticut Society of CPAs.
Ronald M. Lindsay, Ph.D.
Dr. Lindsay serves as Sequenom's Executive Vice President, Strategic Planning, previously serving as Executive Vice President of Research and Development. Dr. Lindsay has been a Director since 2003. He served as Vice President, Research and Development, and Chief Science Officer of diaDexus Inc., a biotechnology company, from 2000 to January 2004. From 1997 through 2000, Dr. Lindsay served in various senior management roles with Millennium Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 to 1997, Dr. Lindsay served in various roles with Regeneron Pharmaceuticals Inc., of which he was a founding scientist. He is a director of Arqule Inc., and HistoRx Inc. and received his Ph.D. in Biochemistry from the University of Calgary.